Pharma IQ Members

Market Access

Find out everything you need to know about the latest pricing, reimbursement and market access strategies that will drive your business development.

Contributor: Roger Humphrey
Posted: 22/12/2015
Roger Humphrey
Opportunity almost always comes with risk—and that's especially true for life sciences companies looking at new markets for new value. While globalization can be a means for driving value, JLL’s Life Sciences Outlook calls it a "high risk" strategy from a real estate and facilities perspective. In this Q&A, Roger Humphrey, Executive Managing Director, JLL Life Sciences, talks candidly about the risks associated with seizing that opportunity.
[EventPDF] Full Article »
Posted: 27/09/2012
The Launch of Once-Daily Pill Gives New Hope for Epilepsy Patients

Japanese pharmaceutical giant Eisai has launched a new epilepsy drug in Europe following approval by the European Commission.

Discovered and developed in the United Kingdom, Fycompa® (perampanel) is an important new addition to the treatment of epilepsy in Europe as it has efficacy in difficult-to-treat patients with uncontrolled partial o Full Video »
Contributor: Andrea Charles
Posted: 19/12/2011
Diabetes is a global threat. Researchers estimate that 26.6 million people in the Middle East and North Africa currently have diabetes. Six countries in the region are among the top 10 globally with the highest prevalence of diabetes. In this interview Professor Peter Schwarz, Head of Department of Prevention and Care of Diabetes University Full Podcast »
Contributor:
Posted: 22/12/2015
The phrase Knowledge Exchange (KE) describing collaborations between industry and the academic community is recognised as having been a key factor in the development of the bio-pharmaceutical sector over recent year Full Column »
Contributor:
Posted: 08/12/2015
Disposable Solutions for Biomanufacturing
A dominating focus of today’s single use systems in biomanufacturing is the road towards standardisation between equipment suppliers. The absence of standardisation between single use system suppliers is seen as a key discourager to end users despite the many advantages the format provides to the pharma and biotech production process. Advantages to single use system standardisation include the avoidance of costs for system modification and faster implementation. (2) Full Whitepaper »